Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy

Area of Science:

• Molecular Biology
• Oncology
• Cell Biology

Background:

• Galectins are animal lectins mediating cell recognition and adhesion through carbohydrate-binding domains.
• Aberrant galectin expression is increasingly linked to tumor progression, including proliferation, metastasis, and resistance to therapy.
• Galectins are implicated in autophagy regulation in physiological and pathological conditions, but their role in cancer-associated autophagy is not fully understood.

Purpose of the Study:

• To review the structure and function of galectins at a molecular level.
• To summarize the involvement of galectins in autophagy and cancer progression.
• To highlight the therapeutic potential of targeting galectins and autophagy in cancer treatment.

Main Methods:

• Literature review synthesizing current research on galectins, autophagy, and cancer.
• Analysis of molecular mechanisms underlying galectin-regulated autophagy in various cancers.
• Evaluation of preclinical and clinical data on galectin- and autophagy-targeted cancer therapies.

Main Results:

• Galectins modulate key cancer hallmarks, including proliferation, epithelial-mesenchymal transition (EMT), and immune evasion.
• Galectins influence multiple stages of autophagy, a cellular degradation process crucial for cancer cell survival and adaptation.
• The interplay between galectins and autophagy represents a significant area for developing novel cancer treatment strategies.

Conclusions:

• Galectins are critical regulators of cancer progression through diverse mechanisms, including the modulation of autophagy.
• Targeting the galectin-autophagy axis holds promise for innovative cancer therapies.
• Further elucidation of these mechanisms will accelerate the clinical application of galectin- and autophagy-based treatments.